Search results
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 6 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
25,274 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Los Angeles Capital Management LLC
ETF DAILY NEWS· 18 hours agoLos Angeles Capital Management LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 1st quarter, according to its most recent 13F ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoEarlier in the year, one analyst called results from the cancer vaccine study "transformational."...
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
TipRanks via Yahoo Finance· 5 days agoModerna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can...
Moderna stock is lone omen of bird flu pandemic
Reuters· 5 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
GAMMA Investing LLC Purchases 822 Shares of Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 3 days agoGAMMA Investing LLC grew its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 37.8% in the first quarter, HoldingsChannel reports. The fund owned 2,994 shares ...
COVID summer wave grows, especially in West, with new variant LB.1 on the rise
CBS News· 1 day agoA summertime wave of COVID-19 infections is arriving earlier than last year across a growing share...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoBiotech stocks hit a two-year high in February, but have trended sideways in the months since...
Gateway - Quartz
Quartz· 4 days agoModerna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab in results from a phase-3 clinical trial. The pharma < ...
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Zacks via Yahoo Finance· 1 day agoIts revenues have jumped from $28.3 billion in 2021 to $34.1 billion in 2023. Conclusion While other...